CN116966129A - 稳定的局部用非诺多泮组合物 - Google Patents

稳定的局部用非诺多泮组合物 Download PDF

Info

Publication number
CN116966129A
CN116966129A CN202310774370.XA CN202310774370A CN116966129A CN 116966129 A CN116966129 A CN 116966129A CN 202310774370 A CN202310774370 A CN 202310774370A CN 116966129 A CN116966129 A CN 116966129A
Authority
CN
China
Prior art keywords
composition
fenoldopam
topical
topical composition
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310774370.XA
Other languages
English (en)
Chinese (zh)
Inventor
H·谢弗林
A·莎拉费尔
V·罗森伯格
R·施林格
T·谢舍斯肯因
A·埃弗拉莫夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceutical Industries Ltd
Original Assignee
Taro Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceutical Industries Ltd filed Critical Taro Pharmaceutical Industries Ltd
Publication of CN116966129A publication Critical patent/CN116966129A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202310774370.XA 2019-03-08 2020-03-06 稳定的局部用非诺多泮组合物 Pending CN116966129A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962815893P 2019-03-08 2019-03-08
US62/815,893 2019-03-08
PCT/IB2020/051967 WO2020183322A1 (en) 2019-03-08 2020-03-06 Stable topical compositions of fenoldopam
CN202080019392.XA CN113543773B (zh) 2019-03-08 2020-03-06 稳定的局部用非诺多泮组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080019392.XA Division CN113543773B (zh) 2019-03-08 2020-03-06 稳定的局部用非诺多泮组合物

Publications (1)

Publication Number Publication Date
CN116966129A true CN116966129A (zh) 2023-10-31

Family

ID=69846519

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310774370.XA Pending CN116966129A (zh) 2019-03-08 2020-03-06 稳定的局部用非诺多泮组合物
CN202080019392.XA Expired - Fee Related CN113543773B (zh) 2019-03-08 2020-03-06 稳定的局部用非诺多泮组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080019392.XA Expired - Fee Related CN113543773B (zh) 2019-03-08 2020-03-06 稳定的局部用非诺多泮组合物

Country Status (11)

Country Link
US (2) US11446237B2 (https=)
EP (2) EP3908255B1 (https=)
JP (2) JP7124234B2 (https=)
CN (2) CN116966129A (https=)
AU (2) AU2020236525B2 (https=)
BR (1) BR112021017140A2 (https=)
CA (1) CA3131049A1 (https=)
ES (1) ES2941241T3 (https=)
IL (1) IL286197A (https=)
NZ (1) NZ781774A (https=)
WO (1) WO2020183322A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023257375A1 (en) 2022-04-21 2024-11-07 Glaukos Corporation Ophthalmic topical cream compositions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
ATE210975T1 (de) 1994-06-23 2002-01-15 Procter & Gamble Topisch anzuwendende zubereitungen enthaltend n- acetyl-l-cystein
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
AU3869399A (en) 1998-04-27 1999-11-16 Elan Pharmaceuticals, Inc. Transdermal administration of fenoldopam
JPH11335236A (ja) 1998-05-22 1999-12-07 Shiseido Co Ltd 皮膚外用剤
EP1100476B1 (en) * 1998-07-24 2004-06-16 ALZA Corporation Formulations for the transdermal administration of fenoldopam
US6699497B1 (en) 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
US7442369B1 (en) * 2000-08-09 2008-10-28 Mcneil Ab Compositions of minoxidil
US7358236B1 (en) 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2005079851A2 (en) 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
WO2005108387A2 (en) 2004-05-03 2005-11-17 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
CN101151028A (zh) * 2005-03-03 2008-03-26 Isw集团公司 局部用凝胶组合物
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
JP2009502206A (ja) 2005-08-03 2009-01-29 ミニュー・セラピューティクス・リミテッド 腫瘍壊死因子アルファ（ＴＮＦ−α）合成および分泌を調節するための、Ｔ細胞におけるＫｖ１．１電位依存性カリウムチャンネルのモデュレーション、およびＴＮＦ−αの有害な高または低レベルを介しての人の疾患または傷害の治療
WO2009052491A2 (en) 2007-10-18 2009-04-23 Geraghty, Erin Fenoldopam formulations and prodrug derivatives
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2009076553A1 (en) 2007-12-11 2009-06-18 Monroe Stephen H Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same
CA2732439A1 (en) 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
JP2011144143A (ja) 2010-01-15 2011-07-28 Shiseido Co Ltd 皮膚外用剤
RU2571277C2 (ru) 2010-10-21 2015-12-20 Галдерма С.А. Композиции геля с бримонидином и способы применения
HUE034480T2 (en) 2011-04-28 2018-02-28 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
FR2991177B1 (fr) 2012-06-01 2014-12-19 Galderma Res & Dev Compositions topiques, contenant un retinoide, de type emulsion huile dans eau sans emulsionnant
AU2014227996B2 (en) * 2013-03-15 2018-08-23 Vapogenix, Inc. Novel analgesic compositions
JP6893075B2 (ja) 2014-08-04 2021-06-23 日東電工株式会社 液性免疫誘導促進用組成物及びワクチン医薬組成物
UA121985C2 (uk) * 2015-01-23 2020-08-25 Др. Редді'З Лабораторіз Лімітед Нефарбуюча гелева композиція для місцевого застосування, яка містить німесулід
EP3506906A4 (en) * 2016-08-31 2020-08-12 Taro Pharmaceutical Industries Ltd. TOPICAL FORMULATIONS OF FENOLDOPAM FOR THE TREATMENT OF SKIN DISORDERS
MX2020004187A (es) * 2017-10-24 2020-09-21 Glenmark Pharmaceuticals Ltd Composicion farmaceutica topica de adapaleno y minociclina.

Also Published As

Publication number Publication date
EP4218719A2 (en) 2023-08-02
EP3908255B1 (en) 2023-01-11
WO2020183322A1 (en) 2020-09-17
ES2941241T3 (es) 2023-05-19
JP2022160648A (ja) 2022-10-19
CN113543773B (zh) 2023-07-14
EP3908255A1 (en) 2021-11-17
BR112021017140A2 (pt) 2021-11-09
US20230059107A1 (en) 2023-02-23
AU2022202941A1 (en) 2022-05-26
EP4218719A3 (en) 2023-09-20
US11446237B2 (en) 2022-09-20
JP2022515569A (ja) 2022-02-18
AU2020236525B2 (en) 2022-02-03
CA3131049A1 (en) 2020-09-17
IL286197A (en) 2021-10-31
NZ781774A (en) 2023-03-31
CN113543773A (zh) 2021-10-22
AU2020236525A1 (en) 2021-11-04
JP7124234B2 (ja) 2022-08-23
US20220040089A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
JP7324210B2 (ja) トファシチニブを含む局所製剤
EP2863886B1 (en) Compositions and methods for topical delivery of prostaglandins to subcutaneous fat
KR20080092373A (ko) 치료용 조성물
US20240382502A1 (en) Compositions and methods for deep dermal drug delivery
EP4196477A1 (en) Tofacitinib-containing anhydrous elastomer-based gel formulations
WO2023016583A1 (zh) 一种芦可替尼组合物及其用途
TWI729371B (zh) 治療搔癢症的組合物與方法
US20230059107A1 (en) Stable topical compositions of fenoldopam
CN114452255A (zh) 一种阿戈美拉汀微乳、微乳凝胶及其制备方法
TWI903311B (zh) 局部藥物組合物、其製備方法及其在醫藥上的用途
US20230172960A1 (en) Topical capecitabine for the treatment of hyperproliferative skin conditions
JP5033381B2 (ja) 外用医薬組成物
US8664205B2 (en) Oil-in-water emulsion lotion containing 22-oxa-1α, 25-dihydroxyvitamin D3 and method of treatment of skin disorder using the same
JP5460766B2 (ja) 外用医薬組成物
JP2024507266A (ja) ヒドロゲル組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用
US12233043B1 (en) Method of transdermal delivery of cannabinoid compositions
JP2007224022A (ja) ２２−オキサ−１α，２５−ジヒドロキシビタミンＤ３を含有する水中油型乳剤性ローション剤
CN119587514A (zh) 稳定性改善的苯酚衍生物的药物组合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination